Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice | Spohn et al. Virology Journal 2010 7 146 http www.virologyj.eom content 7 1 146 VIROLOGY JOURNAL RESEARCH Open Access AVLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice Gunther Spohn 1 GaryT Jennings1 Byron EE Martina2 Iris Keller1 4 Markus Beck1 5 Paul Pumpens3 Albert DME Osterhaus2 and Martin F Bachmann1 Abstract Background Since its first appearance in the USA in 1999 West Nile virus WNV has spread in the Western hemisphere and continues to represent an important public health concern. In the absence of effective treatment there is a medical need for the development of a safe and efficient vaccine. Live attenuated WNV vaccines have shown promise in preclinical and clinical studies but might carry inherent risks due to the possibility of reversion to more virulent forms. Subunit vaccines based on the large envelope E glycoprotein of WNV have therefore been explored as an alternative approach. Although these vaccines were shown to protect from disease in animal models multiple injections and or strong adjuvants were required to reach efficacy underscoring the need for more immunogenic yet safe Dill-based vaccines. Results We produced a conjugate vaccine against WNV consisting of recombinantly expressed domain Ill Dill of the E glycoprotein chemically cross-linked to virus-like particles derived from the recently discovered bacteriophage AP205. ln contrast to isolated Dlll protein which required three administrations to induce detectable antibody titers in mice high titers of Dlll-specific antibodies were induced after a single injection of the conjugate vaccine. These antibodies were able to neutralize the virus in vitro and provided partial protection from a challenge with a lethal dose of WNV. Three injections of the vaccine induced high titers of virus-neutralizing antibodies and completely protected mice from WNV infection. Conclusions The immunogenicity of Dlll can be strongly enhanced by .